Tab Application Banner
  • Users Online: 678
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
LETTER TO EDITOR
Year : 2020  |  Volume : 15  |  Issue : 6  |  Page : 226

We are in charge of treating myositis!


Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana, Turkey

Date of Web Publication18-Jan-2021

Correspondence Address:
Dr. Ilke Coskun Benlidayi
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_54_20

Rights and Permissions

How to cite this article:
Benlidayi IC. We are in charge of treating myositis!. Indian J Rheumatol 2020;15:226

How to cite this URL:
Benlidayi IC. We are in charge of treating myositis!. Indian J Rheumatol [serial online] 2020 [cited 2021 Mar 6];15:226. Available from: https://www.indianjrheumatol.com/text.asp?2020/15/6/226/286218



Inflammatory myopathy/myositis is an umbrella term that encompasses polymyositis, dermatomyositis, sporadic inclusion-body myositis, immune-mediated necrotizing myopathy, and overlap myositis.[1] The prominent clinical feature is subacute to chronic onset of proximal muscle weakness. Patients may also present with extramuscular symptoms indicating the systemic inflammatory feature of the disease.[2],[3] Multiorgan involvement may include the skin, gastrointestinal system, joints, lungs, and heart.[3] Muscle enzymes, myositis-specific antibodies, electroneuromyography, skeletal muscle imaging, and muscle biopsy are used for diagnosis.[2]

Management of idiopathic inflammatory myositis should involve both pharmacological and nonpharmacological strategies. Pharmacological options vary including corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, cyclophosphamide, cyclosporine, tacrolimus, rituximab, and some other biological disease-modifying anti-rheumatic drugs. On the other hand, nonpharmacological options such as physical, occupational, and speech therapy should be directed meticulously according to patients' needs.[2]

In this regard, a multidisciplinary approach is desired for the management of inflammatory myositis. Hence, we are all in charge of treating myositis [Figure 1]. Let's “collect the inflammatory cells,” “patch the vacuoles,” and “remove the aggregates”!
Figure 1: Cartoon

Click here to view




 
  References Top

1.
Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018;17:816-28.  Back to cited text no. 1
    
2.
Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: Clinical approach and management. Front Neurol 2016;7:64.  Back to cited text no. 2
    
3.
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol 2018;14:269-78.  Back to cited text no. 3
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References
Article Figures

 Article Access Statistics
    Viewed944    
    Printed54    
    Emailed0    
    PDF Downloaded76    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]